Psychiatry and
Behavioral Sciences

Cholesterol Lowering Agents to Slow Progression of Alzheimer’s Disease (CLASP Study)

[This study is no longer recruiting subjects.]

Researchers have found that lowering cholesterol levels with certain medications may have a positive impact on brain function and may reduce the risk of Alzheimer’s disease. The CLASP Study is a national clinical research study designed to examine the effectiveness of Simvastatin (Zocor), a widely used cholesterol lowering medication, in slowing memory decline in individuals with Alzheimer’s disease. The CLASP Study is sponsored by the Alzheimer’s Disease Cooperative Study and funded by the National Institute on Aging (NIA). Participants in this study will be given either Simvastatin or placebo (inactive pill) for 21 months. Throughout the study, participants will be assessed regularly by physicians and other qualified health care professionals. Volunteers must be diagnosed with mild to moderate Alzheimer's disease and have a study partner who is familiar with the participant’s health to accompany the individual to all eight clinic visits during the 21-month period.

 

Stanford Medicine Resources:

Footer Links: